+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global MEK Inhibitors Market 2019-2023 - Product Image

Global MEK Inhibitors Market 2019-2023

  • ID: 4825173
  • Report
  • August 2019
  • Region: Global
  • 136 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global MEK Inhibitors Market 2019-2023: About the market

MEK is a drug that inhibits the mitogen-activated extracellular signal-regulated kinase. The MEK inhibitors market analysis considers sale from MEKINIST, COTELLIC, and MEKTOVI. Our analysis also considers the MEK inhibitors in Asia, Europe, North America, and ROW. In 2018, the MEKINIST segment had a significant share, and this trend is expected to continue over the forecast period. Factors such as treatment of melanoma, presence of protein kinase, and cellular proliferation will play a significant role in the MEKINIST segment to maintain its market position. Also, our global MEK inhibitors market report looks at factors such as high target affinity and specificity of MEK inhibitors, use of combination therapies, and strategic alliances. However, the uncertainties in abundance of substitutes, adverse effects of MEK inhibitors and stringent regulations may hamper the growth MEK inhibitors market over the forecast period.

Global MEK Inhibitors Market: Overview

High target affinity and specificity of MEK inhibitors

MEK inhibitors are the small molecule targeted therapy drugs that are used for the treatment of carcinomas. These drugs act on MEK directly and hinder its activity and help in decreasing the growth of the tumor. This demand for high target affinity and specificity of MEK inhibitors will lead to the expansion of the global MEK inhibitors market at a CAGR of over 8% during the forecast period.

Use of protein biomarkers in the diagnosis of NSCLC

Protein biomarkers help in detecting tumors as they can differentiate between the morphological as well as the chemical features of the protein in normal cells and abnormal cells. A major factor that is increasing the popularity of protein biomarkers for the detection of NSCLC is their efficacy in the diagnosis of the condition. The use of predictive protein biomarkers can also lower the cost of treatment as well as the adverse effects associated with it. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, global MEK inhibitors market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading MEK inhibitors manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc.

Also, global MEK inhibitors, market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • MEKINIST - Market size and forecast 2018-2023
  • COTELLIC - Market size and forecast 2018-2023
  • MEKTOVI - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Special drug designations
  • Expanded application
  • Use of protein biomarkers in diagnosis of NSCLC
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: MEKINIST - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: MEKINIST - Year-over-year growth 2019-2023 (%)
Exhibit 22: COTELLIC - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: COTELLIC - Year-over-year growth 2019-2023 (%)
Exhibit 24: MEKTOVI - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: MEKTOVI - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Country-wise age-standardized rate of melanomas in Europe 2018
Exhibit 35: Country-wise prevalence rate of NSCLC in Europe 2008
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Alternative therapies based on MEK inhibitors for various oncology indications
Exhibit 47: Side effects of MEK and BRAF inhibitors
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Drug designations
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AstraZeneca Plc - Vendor overview
Exhibit 56: AstraZeneca Plc - Business segments
Exhibit 57: AstraZeneca Plc - Organizational developments
Exhibit 58: AstraZeneca Plc - Geographic focus
Exhibit 59: AstraZeneca Plc - Key offerings
Exhibit 60: AstraZeneca Plc - Key customers
Exhibit 61: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 63: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 64: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 67: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 68: Novartis AG - Vendor overview
Exhibit 69: Novartis AG - Business segments
Exhibit 70: Novartis AG - Organizational developments
Exhibit 71: Novartis AG - Geographic focus
Exhibit 72: Novartis AG - Segment focus
Exhibit 73: Novartis AG - Key offerings
Exhibit 74: Novartis AG - Key customers
Exhibit 75: Ono Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 76: Ono Pharmaceutical Co. Ltd. - Business segments
Exhibit 77: Ono Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 78: Ono Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 79: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibit 80: Ono Pharmaceutical Co. Ltd. - Key customers
Exhibit 81: Pfizer Inc. - Vendor overview
Exhibit 82: Pfizer Inc. - Business segments
Exhibit 83: Pfizer Inc. - Organizational developments
Exhibit 84: Pfizer Inc. - Geographic focus
Exhibit 85: Pfizer Inc. - Segment focus
Exhibit 86: Pfizer Inc. - Key offerings
Exhibit 87: Pfizer Inc. - Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global MEK inhibitors market: AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the use of protein biomarkers in the diagnosis of NSCLC.”

According to the report, one of the major drivers for this market is the high target affinity and specificity of MEK inhibitors.

Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of MEK inhibitors.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll